-2021财年上半年收入增加63.6%，达到1170万美元-
西安2021年8月17日 /美通社/ -- 西安天美生物科技股份有限公司（纳斯达克代码：BON））（“天美生物”或“公司”），一家在天然、健康和个人护理行业提供关键活性成分及解决方案的领先供应商，今天宣布其截至2021年3月31日的6个月的半年度财务业绩。
2021年上半年财务亮点
管理层讨论
“我们创新高的收入和收益的加速增长是我们作为上市公司首次公布业绩的很好的答卷，并为天美作为上市公司起了一个良好的开端，”天美生物的董事长兼CEO胡永卫表示，“我们的行业知名品牌与优质产品相结合，为我们的客户带来了很高的价值主张，并为我们在这个市场需求增长的时期提升市场份额提供了坚实的基础。今年到目前为止，我们在新业务上取得的成果以及正在开发中的产品销售的趋势也令我感到鼓舞。我们将继续优化我们的销售策略，着重大型企业客户，并降低我们的制造成本，以支持可持续的长期盈利能力。我要感谢我们辛勤工作的团队，公司的成功离不开他们的不懈努力，以及我们忠实的客户对我们的信任。我们在玉门工厂的扩张的时机非常好。目前，市场对我们产品需求旺盛，产能的提升提高，将为公司销售增长提供保障，更好满足当前市场客户的需求。而公司新生产基地可以帮助我们实现这一目标。我们相信，我们的独有的技术、商业模式和战略将使我们能够获得更多的市场份额，并保持增长势头。”
2021上半年产品（按类别）与上年相比增长总结：
收入增加（减少） | 毛利润增加（减少） | |
香料原料 | 133.0% | 226.9% |
膳食补充剂（固体饮料） | 338.4% | 306.0% |
生物活性食品原料 | (69.7%) | (79.0%) |
香料原料
膳食补充剂（固体饮料）
生物活性食品原料
管理费用从截至2020年3月31日的六个月的811,799美元减少到2021年同期的679,635美元，减少了132,164美元，或大约16.3%，主要是由于截至2021年3月31日的六个月内专业咨询服务费用减少了197,327美元。公司在截至2020年3月31日的六个月内产生了较高的咨询服务费用和较高的审计费用。
政府补贴以补贴形式获得并确认为其他营业收入，在截至2021年3月31日和2020年3月31日的六个月里，总额分别为446,910美元和332,418美元。
净利润从截至2020年3月31日的六个月的160万美元增加到2021年同期的230万美元。
经营活动产生的净现金在截至2021年3月31日的六个月期间为200万美元，2020年同期为50万美元。
稀释后每股收益（“EPS”）为0.40美元，2020年同期为0.30美元。
我们鼓励投资者查阅公司完整的财务报表和相关的披露资料，以了解更多信息。这些材料可在.中查阅。
报告期后事件
投资者电话会议和网络直播
讨论公司2021年上半年财务业绩的网络直播将于2021年8月17日美国东部时间上午8:30开始。网络直播和相关PPT的获取可以访问公司的投资者网站 。对于无法观看网络直播的人，在活动结束后公司将在网站上提供录制版本。
预先登记：
预先登记的呼叫者将得到一个会议密码和独有PIN码，可以立即进入电话会议并绕过接线员。与会者可以在任何时候进行预先登记，包括在电话会议开始后。
无法互联网接入或无法预先登记的人可以通过以下电话拨入：
美国免费电话：1-866-777-2509
国际收费电话：1-412-317-5413
西安天美生物科技股份有限公司
西安天美生物专注于膳食营养补充剂的生物活性成分的生产，如为食品制造商提供天然益生元；个人护理成分的生产，如为香水香料制造商提供从植物来源的香料原料，天然复配膳食补充剂生产，如固体饮料。欲了解更多信息，请访问公司网站：.
安全港声明
本新闻稿包含了1995年《私人证券诉讼改革法案》中的前瞻性声明。前瞻性声明包括了有关公司计划、目标、战略、未来事件或业绩的声明，以及其他假设和不包含历史事件的声明。当公司使用诸如“可能”、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“计划”、“估计”等或其他类似的表达方式，并不与历史事件有关，就是在做前瞻性声明。前瞻性声明不是对公司未来业绩的保证，涉及风险和不确定性，可能会导致实际结果与前瞻性声明中讨论的公司预期有实质性的差异。这些陈述受不确定性和风险因素的印象，包括但不限于：公司的目标和战略、公司的未来业务发展、公司产品和服务的需求、技术的变化、经济状况、中国天然健康和个人护理行业的发展及公司希望发展的其他国际市场、声誉和品牌、竞争和定价的影响、政府法规、中国及公司希望发展的其他国际市场的经济和商业状况的变动，以及与上述任何情况相关的假设和公司提交给SEC报告中所陈述的其他风险。因此，我们提醒投资者不要过分依赖本新闻稿中的前瞻性陈述。公司向SEC提交的文件中讨论了其他因素，这些文件可在 上查阅。公司不承担公开修订本声明日期之后出现的事件或情况的前瞻性声明的义务。
更多信息，请联系：
In the United States: | In China: |
Maggie Zhang | Impact IR | Sophie Zhang | Impact IR |
Phone: (646) 893-8916 | Email: |
Email: |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(UNAUDITED) | ||||||||
As of | ||||||||
March 31, 2021 | September 30, 2020 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash | $ | 1,040,607 | $ | 53,106 | ||||
Accounts receivable, net | 8,869,747 | 5,771,008 | ||||||
Inventories, net | 1,446,516 | 1,016,442 | ||||||
Advance to suppliers, net | 1,894,359 | 3,491,145 | ||||||
Deferred initial public offering costs | 984,162 | 510,079 | ||||||
Prepaid expenses and other current assets | 106,786 | 7,434 | ||||||
TOTAL CURRENT ASSETS | 14,342,177 | 10,840,214 | ||||||
Property, plant and equipment, net | 14,590,470 | 14,171,963 | ||||||
Intangible assets, net | 144,126 | 140,993 | ||||||
Right-of-use lease assets, net | 229,532 | |||||||
Deferred tax assets, net | 37,032 | 49,059 | ||||||
TOTAL ASSETS | $ | 29,343,337 | $ | 25,202,229 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Short-term loans | $ | 1,823,215 | $ | 1,289,081 | ||||
Current portion of long-term loans | 2,318,528 | 1,227,346 | ||||||
Third party loans | - | 690,327 | ||||||
Accounts payable | 577,311 | 1,288,629 | ||||||
Due to related parties | 1,019,128 | 2,322,990 | ||||||
Taxes payable | 5,688,786 | 4,402,625 | ||||||
Accrued expenses and other current liabilities | 1,275,936 | 442,582 | ||||||
Finance lease liabilities, current | 148,983 | 33,389 | ||||||
Operating lease liability, current | 57,051 | |||||||
TOTAL CURRENT LIABILITIES | $ | 12,908,938 | $ | 11,696,969 | ||||
Long-term loans | 2,106,180 | 2,482,251 | ||||||
Finance lease liabilities, noncurrent | 110,499 | - | ||||||
Operating lease liability, noncurrent | 176,701 | - | ||||||
TOTAL LIABILITIES | 15,302,318 | 14,179,220 | ||||||
COMMITMENTS AND CONTINGENCIES EQUITY | ||||||||
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, | $ | 580 | $ | 580 | ||||
Additional paid in capital | 5,567,873 | 5,251,205 | ||||||
Statutory reserve | 579,922 | 579,922 | ||||||
Retained earnings | 7,384,071 | 5,072,672 | ||||||
Accumulated other comprehensive income (loss) | 15,421 | (388,102) | ||||||
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY | 13,547,867 | 10,516,277 | ||||||
Non-controlling interest | 493,152 | 506,732 | ||||||
Total equity | 14,041,019 | 11,023,009 | ||||||
TOTAL LIABILITIES AND EQUITY | $ | 29,343,337 | $ | 25,202,229 | ||||
*Retrospectively restated for effect of 1-for-3 shares reverse split. | ||||||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME | ||||||||
(UNAUDITED) | ||||||||
For the six months ended March 31, | ||||||||
2021 | 2020 | |||||||
REVENUE | $ | 11,698,830 | $ | 7,149,785 | ||||
COST OF REVENUE | (8,325,148) | (4,597,617) | ||||||
GROSS PROFIT | 3,373,682 | 2,552,168 | ||||||
OPERATING EXPENSES | ||||||||
Selling expenses | (52,666) | (59,765) | ||||||
General and administrative expenses | (679,635) | (811,799) | ||||||
Research and development expenses | (106,998) | (128,481) | ||||||
Total operating expenses | (839,299) | (1,000,045) | ||||||
INCOME FROM OPERATIONS | 2,534,383 | 1,552,123 | ||||||
OTHER INCOME (EXPENSES) | ||||||||
Interest income | 294 | 451 | ||||||
Interest expense | (197,168) | (172,913) | ||||||
Unrealized foreign transaction exchange gain (loss) | (65,691) | (4,300) | ||||||
Government subsidies | 446,910 | 332,418 | ||||||
Other income | 41,548 | 136,482 | ||||||
Total other income (expenses) | 225,893 | 292,138 | ||||||
INCOME BEFORE INCOME TAX PROVISION | 2,760,276 | 1,844,261 | ||||||
INCOME TAX PROVISION | (465,077) | (249,766) | ||||||
NET INCOME | 2,295,199 | 1,594,495 | ||||||
Less: net income (loss) attributable to non-controlling interest | (16,200) | 61,317 | ||||||
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | 2,311,399 | 1,533,178 | ||||||
OTHER COMPREHENSIVE INCOME (LOSS) | ||||||||
Total foreign currency translation adjustment | 406,143 | 32,468 | ||||||
TOTAL COMPREHENSIVE INCOME | 2,701,342 | 1,626,963 | ||||||
Less: comprehensive income (loss) attributable to non-controlling | (13,580) | 59,939 | ||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON | $ | 2,714,922 | $ | 1,567,024 | ||||
EARNINGS PER SHARE | ||||||||
Basic and diluted | $ | 0.40 | $ | 0.30 | ||||
WEIGHTED AVERAGE NUMBER OF SHARES | ||||||||
Basic and diluted* | 5,800,000 | 5,166,667 | ||||||
* Retrospectively restated for effect of reverse split.
BON NATURAL LIFE LIMITED AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(UNAUDITED) | ||||||||
For the six months ended March 31, | ||||||||
2021 | 2020 | |||||||
Cash flows from operating activities | ||||||||
Net income | $ | 2,295,199 | $ | 1,594,495 | ||||
Adjustments to reconcile net income to cash provided by operating | ||||||||
Allowance for doubtful accounts | 6,323 | 23,316 | ||||||
Depreciation and amortization | 117,888 | 134,457 | ||||||
Deferred income tax | 13,879 | (19,459) | ||||||
Amortization of operating lease right-of-use assets | 26,195 | - | ||||||
Unrealized foreign currency exchange loss | 65,691 | 4,300 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (2,898,493) | (410,656) | ||||||
Inventories | (391,958) | 482,914 | ||||||
Advance to suppliers | 1,738,442 | (1,787,999) | ||||||
Prepaid expenses and other current assets | (99,108) | 17,251 | ||||||
Accounts payable | (760,103) | (809,818) | ||||||
Operating lease liabilities | (21,975) | - | ||||||
Taxes payable | 1,120,847 | 905,514 | ||||||
Accrued expenses and other current liabilities | 786,942 | 412,845 | ||||||
Net cash provided by operating activities | 1,999,769 | 547,160 | ||||||
Cash flows from investing activities | ||||||||
Purchase of property and equipment | (715) | (26,957) | ||||||
Capital expenditures on construction-in-progress | - | (403,911) | ||||||
Net cash used in investing activities | (715) | (430,868) | ||||||
Cash flows from financing activities | ||||||||
Proceeds from short-term loans | 943,517 | 601,833 | ||||||
Proceeds from long-term loans | 685,067 | 41,001 | ||||||
Repayment of short-term loans | (457,729) | (1,211,475) | ||||||
Repayment of long-term loans | (109,382) | - | ||||||
Proceeds from (repayment of) borrowings from related parties | (1,391,813) | 393,367 | ||||||
Proceeds from (repayment of) third party loans | (716,574) | 76,797 | ||||||
Principal payment from (repayment of) finance lease | 254,970 | (195,863) | ||||||
Payment for deferred initial public offering costs | (155,557) | (42,705) | ||||||
Net cash used in financing activities | (947,501) | (337,045) | ||||||
Effect of changes of foreign exchange rates on cash | (64,052) | 15,605 | ||||||
Net increase (decrease) in cash | 987,501 | (205,148) | ||||||
Cash, beginning of year | 53,106 | 293,771 | ||||||
Cash, end of year | $ | 1,040,607 | $ | 88,623 | ||||
Supplemental disclosure of cash flow information | ||||||||
Cash paid for interest expense | $ | 215,268 | $ | 172,913 | ||||
Cash paid for income tax | $ | 1,424 | $ | - | ||||
Supplemental disclosure of non-cash investing and financing activities | ||||||||
Amortization of share-based compensation for initial public offering | $ | 316,668 | $ | - | ||||
Right-of-use assets obtained in exchange for operating lease | 255,811 | - | ||||||
京公网安备 11010502030597号
